BNTX

BioNTech (BNTX) Stock Price

Closed
BNTX
$80.76
-$1.79(-2.16%)

Content updated: 2026-11-22 22:22:02

Yesterday's Close
$82.55
Today's Open
$82.80
Today's High
$82.80
Today's Low
$79.95
Volume
709.97K shares
52-Week Range
$79.50-$124.00

As of 2026-11-22 22:22:02, BioNTech (BNTX) was quoted at $80.76, a change of -$1.79 (-2.16%) from the previous close. The day's range was $79.95–$82.80, and the 52-week range was $79.50–$124.00.

Why Is BioNTech (BNTX) Stock Falling?

AI Stock Price Analysis

Content updated: 2026-11-20 21:53:27

BNTX opened lower, spiked to $82.86, then gave back the gain and settled near volume-weighted average price (VWAP), down 0.45% to $80.97 on volume near 1.59x baseline. The Nov 17 priority review voucher purchase remains the latest verifiable company news.

Past 1W-5.41%Period Low $80.27Period High $87.00
Past 1M-10.77%Period Low $80.27Period High $92.72
Past 3M-28.99%Period Low $80.27Period High $116.87
Past 1Y-16.97%Period Low $79.52Period High $124.00

About BioNTech (BNTX)

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.
Ticker / Exchanges
BNTX / NASDAQ
Industry / Sector
Biotechnology / Healthcare
CEO
Ugur Sahin
Headquarters
Mainz,RP,DE
Listing Date
2019-10-10

Recent Company Events

  • 2026-11-03
    Earnings Report · ReleasedThe 2026/Q3 earnings report has been released.

BioNTech (BNTX) Derivatives Trading

BNTXTrade
Stocks

Trade U.S., Hong Kong, Japanese, and South Korean stocks directly. Selected U.S., Hong Kong, and South Korean stocks support 24/7 trading. You hold actual shares. Corporate actions such as dividends and stock splits are handled according to market rules.

BNTXTrade
CFD

Trade stock price movements through CFDs without holding the underlying shares. CFDs support long and short positions and leveraged trading. Be aware of spreads, trading fees, overnight fees, and liquidation risk.

BioNTech (BNTX) Company Financials

Valuation and Shares

Market Cap
$20.07B
P/E Ratio (TTM)
-12.55
P/B Ratio
1.03
Shares Outstanding
247.92M shares
Float Shares
106.00M shares
Dividend Yield (TTM)
0.00%

Latest Reported Financials

2026 Q3 Financials

Report Release Date: 2026-11-03

Operating Revenue (Actual)

$1.60B

Same Period Last Year: -17.91%

Earnings per Share (Actual)

$0.90

Same Period Last Year: +690.71%

Financials · Actuals

Actual Value2022/Annual2023/Annual2024/Annual2025/Annual
Revenue$18.99B$4.19B$3.01B$3.14B
Net Profit$10.35B$1.02B-$729.72M-$1.24B
Operating Cash Flow$14.89B$5.89B$228.24M$500.38M

BNTX FAQ

What is the current stock price of BioNTech (BNTX)?

x
As of 2026-11-22 22:22 (UTC+8), the latest available quote for BioNTech (BNTX) is $80.76 USD, with a change of -$1.79 USD (-2.16%) from the previous trading day's close. Current market status: Closed.

Which exchange is BNTX listed on?

x

How has BioNTech stock performed over the past month?

x

What is the market cap of BioNTech?

x

What are BioNTech's latest financial results?

x

What factors may affect the stock price of BioNTech (BNTX)?

x

Other Trading Markets

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.